U.S. Pharmaceuticals & Biotech Pure Equity Growth

Krystal Biotech

Market Cap: US$8.6b

A commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States.

Corcept Therapeutics

Market Cap: US$7.6b

A biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.

Camurus

Market Cap: US$30.6b

A biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia.

BioArctic

Market Cap: US$27.9b

Develops biological drugs for patients with central nervous system disorders in Sweden.

Bonesupport Holding

Market Cap: US$14.8b

An orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in the United States, Europe, and internationally.

CARsgen Therapeutics Holdings

Market Cap: US$10.2b

An investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies, solid tumors, and autoimmune diseases in China.

Neuren Pharmaceuticals

Market Cap: US$1.7b

A biopharmaceutical company, develops drugs for the treatment of neurological disorders.

Kuros Biosciences

Market Cap: US$738.8m

Engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally.

Zevra Therapeutics

Market Cap: US$643.2m

A commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States.

Clarity Pharmaceuticals

Market Cap: US$859.9m

A clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States.

BioPorto

Market Cap: US$524.8m

An in-vitro diagnostics company, focuses on developing biomarker tests to help clinicians detect the kidney injury in critically ill patients at earlier stage in Denmark, rest of Europe, North America, and Asia.

Marker Therapeutics

Market Cap: US$23.7m

A clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States.